• 1 Year Returns: 14.62%
• 3 Year Returns: 19.48%
• 5 Year Returns: 14.45%

• Pharmaceuticals | 73.51%
• Labs & Life Sciences Services | 19.66%
• Retail - Speciality | 2.69%
• Miscellaneous | 2.16%
• Others | 1.98%

• Sun Pharmaceutical Industries Ltd | 13.31%
• Lupin Limited | 7.25%
• Divi's Laboratories Ltd | 6.52%
• Cipla Ltd | 6.03%
• Apollo Hospitals Enterprise Limited | 5.30%

• Equity | 97.32%
• Cash & Equivalents | 2.68%

The alpha ratio for the Nippon India Pharma Fund is -0.77

Alpha is the excess return of a fund compared to its expected return, based on its beta and the risk-free rate. Positive alpha indicates that the fund has outperformed its expected return, while negative alpha suggests underperformance.

The volatility or standard deviation for the Nippon India Pharma Fund is 11.67

Standard deviation measures the volatility or risk associated with the returns of a mutual fund. A higher standard deviation indicates higher volatility, suggesting that the returns of the mutual fund are more spread out from the average. On the other hand, a lower standard deviation implies lower volatility and a more stable performance.

The Sharpe ratio for the Nippon India Pharma Fund is 0.88

The Sharpe ratio is a measure of risk-adjusted return that evaluates the performance of a mutual fund, by adjusting for its risk. Higher Sharpe ratio indicates a better risk-adjusted performance. A positive Sharpe ratio indicates that the MF has provided a return in excess of the risk-free rate for the amount of risk taken. Conversely, a negative Sharpe ratio suggests that the MF did not adequately compensate for the risk.

The Sortino Ratio for the Nippon India Pharma Fund is 0.10

The Sortino ratio of a mutual fund is a measure of its risk-adjusted return, considering only downside volatility. It helps investors evaluate how well a fund is performing relative to its downside risk. A higher Sortino ratio (value >1) means the fund generates better returns for the downside risk taken.